New evidence
Vitamin E plus levocarnitine slashed cardiac event odds by 73% in chemo patients — but the combo was tested in only one small trial among 28 studies.
This is the first systematic review to flag this supplement pairing as potentially protective during anthracycline chemotherapy, but with just 858 patients across all trials and no specified dose, it’s a promising lead — not a recommendation.
In a network meta-analysis of 28 randomized trials, a combination of vitamin E and levocarnitine (a form of L-carnitine) was tied to a 73% reduction in cardiac events for patients on anthracycline chemotherapy. However, this result comes from a single small study within the review, and the dose used wasn’t reported, so the finding needs replication before it can be relied upon.
Where this fits in the evidence
This is among the first studies we've indexed on L-Carnitine for Reduced Cardiac Event — treat it as an early signal until more research accumulates.
The study
- Systematic Review
- n = 858
- 2025-09-03
- Frontiers in cardiovascular medicine
This is a plain-language summary of a research finding, not medical advice. Pillser surfaces research signals to help you decide what's worth investigating — always consult a qualified professional before changing what you take.